Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of South Carolina, Columbia, SC, USA.
Ann Am Thorac Soc. 2013 Apr;10(2):115-20. doi: 10.1513/AnnalsATS.201209-081OC.
Obstructive sleep apnea (OSA) is an independent risk factor for the development of insulin resistance (IR). Treatment with continuous positive airway pressure (CPAP) for OSA has shown conflicting results on IR.
To conduct a meta-analysis of randomized controlled trials (RCTs) that have evaluated the effect of CPAP on a validated index of IR, the homeostasis model assessment of insulin resistance (HOMA-IR).
PubMed and Embase were searched through August 10, 2012. Two independent reviewers screened citations to identify trials of the effect of CPAP on HOMA-IR. Data were extracted for postintervention HOMA-IR values.
A total of five studies that enrolled 244 subjects (83% male) met the inclusion criteria. None of the subjects in the included studies had diabetes. The pooled estimate of the difference in means in HOMA-IR between the CPAP and sham CPAP/control groups was -0.44 (95% confidence interval, -0.82 to -0.06; P = 0.02). The funnel plot does not suggest the presence of any publication bias. The I-squared index for the data on difference in means in HOMA-IR between the CPAP and sham CPAP/control groups was 0.00 (P = 0.61).
The pooled estimate of RCTs shows a favorable effect of CPAP on insulin resistance as measured by HOMA-IR in patients with OSA without diabetes. The effect size on HOMA-IR is modest, but not insignificant, when compared with the effects of thiazolidinedione in nondiabetic patients with metabolic syndrome. Further research and RCTs are warranted involving a larger number of patients and longer treatment periods to determine the beneficial effects of CPAP on IR.
阻塞性睡眠呼吸暂停(OSA)是胰岛素抵抗(IR)发展的独立危险因素。针对 OSA 的持续气道正压通气(CPAP)治疗对 IR 的影响结果不一。
对评估 CPAP 对胰岛素抵抗的验证指标(稳态模型评估的胰岛素抵抗指数,HOMA-IR)的影响的随机对照试验(RCT)进行 meta 分析。
检索 PubMed 和 Embase 数据库,检索时间截至 2012 年 8 月 10 日。两位独立的评审员筛选引文以确定 CPAP 对 HOMA-IR 影响的试验。提取干预后 HOMA-IR 值的数据。
共有 5 项纳入 244 例患者(83%为男性)的研究符合纳入标准。纳入研究的所有患者均无糖尿病。CPAP 组和 sham CPAP/对照组的 HOMA-IR 差值的合并估计值为-0.44(95%置信区间,-0.82 至-0.06;P = 0.02)。漏斗图表明不存在任何发表偏倚。CPAP 组和 sham CPAP/对照组的 HOMA-IR 差值的均数差异数据的 I2 指数为 0.00(P = 0.61)。
RCT 的汇总估计值表明,CPAP 对 OSA 患者的胰岛素抵抗有有利影响,且可以通过 HOMA-IR 来测量。与代谢综合征的非糖尿病患者使用噻唑烷二酮的效果相比,CPAP 对 HOMA-IR 的影响适度,但并非无意义。需要进一步研究和 RCT 来确定 CPAP 对 IR 的有益影响,涉及更多患者和更长的治疗时间。